Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 303M
+0.16%-1.74%+1.16%+18.14% 49.81B
-1.11%-2.84%+420.04%+505.15% 44.06B
-0.21%+0.37%+36.88%+17.32% 42.99B
-1.95%-3.33%+8.29%+73.25% 40.88B
-0.94%-1.77%+18.34%+46.84% 33.11B
-1.11%-4.20%+25.49%+119.78% 16.58B
+6.10%+4.40% - - 17.27B
+0.96%-1.11%+12.74%+29.34% 14.63B
-1.12%-3.46%+76.50%+39.37% 13.76B
Average +0.65%-1.37%+74.93%+106.15% 30.34B
Weighted average by Cap. -0.25%-1.50%+88.96%+122.77%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-